1. Current drug therapy for colorectal cancer
   Lucy Mohapatra et al, 2024, Colorectal Cancer CrossRef
2. Discovering relationships between nuclear receptor signaling pathways, genes, and tissues in Transcriptomine
   Lauren B. Becnel et al, 2017, Science Signaling CrossRef
3. Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer
   Melanie M. Frigault et al, 2020, JCO Precision Oncology CrossRef
4. Long non-coding RNAs in anti-cancer drug resistance
   Qin-nan Chen et al, 2017, Oncotarget CrossRef
5. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
   null null et al, 2017, Nature Reviews Clinical Oncology CrossRef
6. Synergistic Effects of the Combinational Use of Escitalopram Oxalate and 5-Fluorouracil on the Inhibition of Gastric Cancer SNU-1 Cells
   Vincent Chin-Hung Chen et al, 2022, International Journal of Molecular Sciences CrossRef
7. Curcumin: Its Role in Regulation of HIF-1α in Gastric Cancer
   Tapan K. Barik et al, 2017, Role of Transcription Factors in Gastrointestinal Malignancies CrossRef
8. Corosolic acid reduces 5‑FU chemoresistance in human gastric cancer cells by activating AMPK
   Jun Park et al, 2018, Molecular Medicine Reports CrossRef
9. Comprehensive review of targeted therapy for colorectal cancer
   Yuan-Hong Xie et al, 2020, Signal Transduction and Targeted Therapy CrossRef
10. Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer
    Jooseok Kim et al, 2020, Cancers CrossRef